A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation
Abstract Background Currently, there are no effective medications to reverse periodontal disease (PD)-induced bone loss. The objective of this study was to test a new anabolic compound, LLP2A-Ale, or with the combination treatment of mesenchymal stromal cell (MSC), in the treatment of bone loss seco...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-11-01
|
| Series: | BMC Pharmacology and Toxicology |
| Online Access: | http://link.springer.com/article/10.1186/s40360-020-00454-x |